Clinical Trial Update: TATE Versus TACE in Intermediate Stage HCC [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing TATE to transarterial chemoembolization in intermediate-stage hepatocellular carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• TATE

Snippet

Sponsor: Teclison Ltd. | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: TERMINATED